

RICK SCOTT, FLORIDA, CHAIRMAN

DAVID McCORMICK, PENNSYLVANIA  
JAMES C. JUSTICE, WEST VIRGINIA  
TOMMY TUBERVILLE, ALABAMA  
RON JOHNSON, WISCONSIN  
ASHLEY MOODY, FLORIDA  
JON HUSTED, OHIO

KIRSTEN E. GILLIBRAND, NEW YORK, RANKING MEMBER

ELIZABETH WARREN, MASSACHUSETTS  
MARK KELLY, ARIZONA  
RAPHAEL G. WARNOCK, GEORGIA  
ANDY KIM, NEW JERSEY  
ANGELA D. ALSOBROOKS, MARYLAND

## United States Senate

SPECIAL COMMITTEE ON AGING

WASHINGTON, DC 20510-6400

(202) 224-5364

March 4, 2026

Mr. Mike Motz  
Chief Executive Officer  
Walgreen Co.  
108 Wilmot Road  
Deerfield, IL 60015

Dear Mr. Motz:

Thank you for your recent response to our inquiry regarding Walgreen Co.'s approach to address vulnerabilities in foreign drug supply chains and the associated issues of unsafe foreign drugs entering our country. As chairman and ranking member of the U.S. Senate Special Committee on Aging, we are dedicated to ensuring that every American patient has access to safe, affordable, and effective pharmaceuticals. Delivering on this starts by ensuring we have transparency and accountability from foreign drug entities for American patients. To that end, our committee held a hearing on January 29, 2026, entitled [\*Truth in Labeling: Americans Deserve to Know Where Their Drugs Come From\*](#), where we focused on the lack of transparency surrounding the country-of-origin for generic drugs and active pharmaceutical ingredients (APIs) sold in the United States. In addition, we introduced the [\*Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings \(CLEAR LABELS\) Act\*](#), which will require drug labeling to identify the original manufacturers of finished drug products and active pharmaceutical ingredients. We applaud CVS and Walgreen Co. expressing their intentions to implement country-of-origin labeling in their responses to the committee, as pharmacies are often the final point of care with American patients.

We commend Walgreen Co.'s proactive efforts to enhance supply chain management. To gain a deeper understanding of your approach to safeguarding the integrity of the drug supply chain and its impact on patient care, we are requesting additional information about your procurement strategies. Specifically, as noted in our November 10, 2025, letter, we request further clarification on your protocols for the handling of drugs and ingredients exempted from the Food and Drug Administration's (FDA) import bans, and on the implementation of transparent country-of-origin labeling.

We request the following information no later than March 15, 2026:

1. How is Walgreen Co. implementing country-of-origin labeling, and according to which standards?
  - a. What is the anticipated timeline for full implementation by your company?
  - b. Will this information be transparent for consumers, pharmacists, and providers?
  - c. Will this include the API's country of origin?
  - d. Will this information be available in both paper and online formats?
2. Does Walgreen Co. receive notifications from the FDA or suppliers if a product is exempted from an import ban?
  - a. What specific actions are taken when a product is subject to an import ban exemption?
3. Could Walgreen Co. ask its distributors and/or manufacturers for the country-of-origin of the APIs for the generic drugs they dispense?
  - a. If this information is available, how will the procurement of generic drugs be prioritized?
    - i. When does cost influence this decision?
4. To what extent does Walgreen Co. contract directly with suppliers?
  - a. How does Walgreen Co. interface with suppliers and the FDA on quality, specifically when the agency issues Form 483s?
5. Does Walgreen Co. work with the FDA or industry stakeholders in any capacity on the Quality Management Maturity program or any other quality metrics?

Transparency in supply chains and product labeling is critical to ensuring a healthy market and to promoting quality products. Thank you for your continued dialogue with the committee and for your work to ensure the safety and reliability of the pharmaceutical supply chain.

Sincerely,



Rick Scott  
Chairman  
Senate Special Committee on Aging



Kirsten E. Gillibrand  
Ranking Member  
Senate Special Committee on Aging

RICK SCOTT, FLORIDA, CHAIRMAN

DAVID McCORMICK, PENNSYLVANIA  
JAMES C. JUSTICE, WEST VIRGINIA  
TOMMY TUBERVILLE, ALABAMA  
RON JOHNSON, WISCONSIN  
ASHLEY MOODY, FLORIDA  
JON HUSTED, OHIO

KIRSTEN E. GILLIBRAND, NEW YORK, RANKING MEMBER

ELIZABETH WARREN, MASSACHUSETTS  
MARK KELLY, ARIZONA  
RAPHAEL G. WARNOCK, GEORGIA  
ANDY KIM, NEW JERSEY  
ANGELA D. ALSOBROOKS, MARYLAND

## United States Senate

SPECIAL COMMITTEE ON AGING

WASHINGTON, DC 20510-6400

(202) 224-5364

March 4, 2026

Mr. Doug McMillon  
President and Chief Executive Officer  
Walmart Inc.  
1 Customer Drive  
Bentonville, AR 72716

Dear Mr. McMillon:

Thank you for your recent response to our inquiry regarding Walmart Inc.'s approach to address vulnerabilities in foreign drug supply chains and the associated issues of unsafe foreign drugs entering our country. As chairman and ranking member of the U.S. Senate Special Committee on Aging, we are dedicated to ensuring that every American patient has access to safe, affordable, and effective pharmaceuticals. Delivering on this starts by ensuring we have transparency and accountability from foreign drug entities for American patients. To that end, our committee held a hearing on January 29, 2026, entitled [\*Truth in Labeling: Americans Deserve to Know Where Their Drugs Come From\*](#), where we focused on the lack of transparency surrounding the country-of-origin for generic drugs and active pharmaceutical ingredients (APIs) sold in the United States. In addition, we introduced the [\*Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings \(CLEAR LABELS\) Act\*](#), which will require drug labeling to identify the original manufacturers of finished drug products and active pharmaceutical ingredients. We applaud CVS and Walgreens expressing their intentions to implement country-of-origin labeling in their responses to the committee, as pharmacies are often the final point of care with American patients.

We commend Walmart Inc.'s proactive efforts to enhance supply chain management. To gain a deeper understanding of your approach to safeguarding the integrity of the drug supply chain and its impact on patient care, we are requesting additional information about your procurement strategies. Specifically, as noted in our November 10, 2025, letter, we request further clarification on your protocols for the handling of drugs and ingredients exempted from the Food and Drug Administration's (FDA) import bans, and on the implementation of transparent country-of-origin labeling.

We request the following information no later than March 15, 2026:

1. How is Walmart Inc. implementing country-of-origin labeling, and according to which standards?
  - a. What is the anticipated timeline for full implementation by your company?
  - b. Will this information be transparent for consumers, pharmacists, and providers?
  - c. Will this include the API's country of origin?
  - d. Will this information be available in both paper and online formats?
2. Does Walmart Inc. receive notifications from the FDA or suppliers if a product is exempted from an import ban?
  - a. What specific actions are taken when a product is subject to an import ban exemption?
3. Could Walmart Inc. ask its distributors and/or manufacturers for the country-of-origin of the APIs for the generic drugs they dispense?
  - a. If this information is available, how will the procurement of generic drugs be prioritized?
    - i. When does cost influence this decision?
4. To what extent does Walmart Inc. contract directly with suppliers?
  - a. How does Walmart Inc. interface with suppliers and the FDA on quality, specifically when the agency issues Form 483s?
5. Does Walmart Inc. work with the FDA or industry stakeholders in any capacity on the Quality Management Maturity program or any other quality metrics?

Transparency in supply chains and product labeling is critical to ensuring a healthy market and to promoting quality products. Thank you for your continued dialogue with the committee and for your work to ensure the safety and reliability of the pharmaceutical supply chain.

Sincerely,



Rick Scott  
Chairman  
Senate Special Committee on Aging



Kirsten E. Gillibrand  
Ranking Member  
Senate Special Committee on Aging

RICK SCOTT, FLORIDA, CHAIRMAN

DAVID McCORMICK, PENNSYLVANIA  
JAMES C. JUSTICE, WEST VIRGINIA  
TOMMY TUBERVILLE, ALABAMA  
RON JOHNSON, WISCONSIN  
ASHLEY MOODY, FLORIDA  
JON HUSTED, OHIO

KIRSTEN E. GILLIBRAND, NEW YORK, RANKING MEMBER

ELIZABETH WARREN, MASSACHUSETTS  
MARK KELLY, ARIZONA  
RAPHAEL G. WARNOCK, GEORGIA  
ANDY KIM, NEW JERSEY  
ANGELA D. ALSOBROOKS, MARYLAND

## United States Senate

SPECIAL COMMITTEE ON AGING

WASHINGTON, DC 20510-6400

(202) 224-5364

March 4, 2026

Mr. David Joyner  
President and Chief Executive Officer  
CVS Health  
1 CVS Drive  
Woonsocket, RI 02895

Dear Mr. Joyner:

Thank you for your recent response to our inquiry regarding CVS Health's approach to address vulnerabilities in foreign drug supply chains and the associated issues of unsafe foreign drugs entering our country. As chairman and ranking member of the U.S. Senate Special Committee on Aging, we are dedicated to ensuring that every American patient has access to safe, affordable, and effective pharmaceuticals. Delivering on this starts by ensuring we have transparency and accountability from foreign drug entities for American patients. To that end, our committee held a hearing on January 29, 2026, entitled [\*Truth in Labeling: Americans Deserve to Know Where Their Drugs Come From\*](#), where we focused on the lack of transparency surrounding the country-of-origin for generic drugs and active pharmaceutical ingredients (APIs) sold in the United States. In addition, we introduced the [\*Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings \(CLEAR LABELS\) Act\*](#), which will require drug labeling to identify the original manufacturers of finished drug products and active pharmaceutical ingredients. We applaud CVS and Walgreens expressing their intentions to implement country-of-origin labeling in their responses to the committee, as pharmacies are often the final point of care with American patients.


We commend CVS Health's proactive efforts to enhance supply chain management. To gain a deeper understanding of your approach to safeguarding the integrity of the drug supply chain and its impact on patient care, we are requesting additional information about your procurement strategies. Specifically, as noted in our November 10, 2025, letter, we request further clarification on your protocols for the handling of drugs and ingredients exempted from the Food and Drug Administration's (FDA) import bans, and on the implementation of transparent country-of-origin labeling.

We request the following information no later than March 15, 2026:

1. How is CVS Health implementing country-of-origin labeling, and according to which standards?
  - a. What is the anticipated timeline for full implementation by your company?
  - b. Will this information be transparent for consumers, pharmacists, and providers?
  - c. Will this include the API's country of origin?
  - d. Will this information be available in both paper and online formats?
2. Does CVS Health receive notifications from the FDA or suppliers if a product is exempted from an import ban?
  - a. What specific actions are taken when a product is subject to an import ban exemption?
3. Could CVS Health ask its distributors and/or manufacturers for the country-of-origin of the APIs for the generic drugs they dispense?
  - a. If this information is available, how will the procurement of generic drugs be prioritized?
    - i. When does cost influence this decision?
4. To what extent does CVS Health contract directly with suppliers?
  - a. How does CVS Health interface with suppliers and the FDA on quality, specifically when the agency issues Form 483s?
5. Does CVS Health work with the FDA or industry stakeholders in any capacity on the Quality Management Maturity program or any other quality metrics?

Transparency in supply chains and product labeling is critical to ensuring a healthy market and to promoting quality products. Thank you for your continued dialogue with the committee and for your work to ensure the safety and reliability of the pharmaceutical supply chain.

Sincerely,



Rick Scott  
Chairman  
Senate Special Committee on Aging



Kirsten E. Gillibrand  
Ranking Member  
Senate Special Committee on Aging